# Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

> **NCT04923542** · PHASE1,PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 31 (estimated)

## Conditions studied

- Brain Metastases
- HR+ Metastatic Breast Cancer

## Interventions

- **RADIATION:** Stereotactic Radiosurgery (SRS)
- **DRUG:** Abemaciclib
- **DRUG:** Endocrine therapy

## Key facts

- **NCT ID:** NCT04923542
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-30
- **Primary completion:** 2026-11-05
- **Final completion:** 2026-12
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04923542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04923542, "Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04923542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*